Pallas Capital Advisors LLC Has $1.82 Million Stock Holdings in Pfizer Inc. $PFE

Pallas Capital Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 32.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,558 shares of the biopharmaceutical company’s stock after purchasing an additional 18,439 shares during the period. Pallas Capital Advisors LLC’s holdings in Pfizer were worth $1,819,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Perigon Wealth Management LLC boosted its position in Pfizer by 2.3% in the second quarter. Perigon Wealth Management LLC now owns 152,791 shares of the biopharmaceutical company’s stock valued at $3,679,000 after buying an additional 3,427 shares in the last quarter. John Boyer Inc. lifted its holdings in Pfizer by 2.4% during the 2nd quarter. John Boyer Inc. now owns 68,297 shares of the biopharmaceutical company’s stock worth $1,645,000 after buying an additional 1,614 shares in the last quarter. Trust Co. of Vermont bought a new position in Pfizer in the second quarter valued at about $3,822,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Pfizer by 8.5% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,060,742 shares of the biopharmaceutical company’s stock valued at $338,583,000 after purchasing an additional 1,098,549 shares during the last quarter. Finally, Plato Investment Management Ltd boosted its stake in Pfizer by 41.5% in the second quarter. Plato Investment Management Ltd now owns 225,254 shares of the biopharmaceutical company’s stock valued at $5,392,000 after acquiring an additional 66,017 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.8%

PFE stock opened at $28.00 on Friday. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The stock has a market capitalization of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34. The business’s fifty day moving average price is $25.30 and its two-hundred day moving average price is $26.25. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the firm posted $0.78 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 226.32%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. HSBC cut Pfizer from a “buy” rating to a “hold” rating and reduced their target price for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Citigroup raised their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.28.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.